Armata Pharmaceuticals, Inc. · AMEX:ARMP
Armata Pharmaceuticals — Investor Presentation (May 2025)
39 slides from Armata Pharmaceuticals's investor presentation, May 19, 2025
Slide 1: Corporate Presentation
Corporate Presentation May 19, 2025 NYSE American: ARMP
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains “forward-looking” statements that involve risks, uncertainties and assumptions. If the risks or uncertainties materialize or the assumptions prove incorrect, our results may differ materially from those expressed or implied by such forward-lookin
Slide 3: Armata Highlights
Armata Highlights A leading developer of high-purity, high titer, pathogen-specific phage therapeutics: Harnessing significant • Potential alternative to antibiotics – effective while protecting normal human microbiome advantages of phage- • Activity independent of antibiotic resistance, providing c
Slide 4: Phages Are a Novel Biologic Anti-Infective with Distinct MOA from Antibiotics
PHAGE ADVANTAGES Phages Are a Novel Biologic Anti-Infective with Distinct MOA from Antibiotics and Significant Advantages for the Fight Against AMR Key Advantages of Phage Therapy Alternative to broad spectrum antibiotics; Solution to address antibiotic-induced microbial resistance • Reduced antibio
Slide 5: State of Phage Development and Approval
PHAGE ADVANTAGES State of Phage Development and Approval CRITICAL: Prove Phage Therapy Works The phage field has focused on compassionate use cases and individualized medicine. What is urgently needed are definitive pivotal trials that clearly Armata has the capabilities address: and commitment to a
Slide 6: Clinical Pipeline: Multiple Shots on Goal
DIVERSIFIED PIPELINE Clinical Pipeline: Multiple Shots on Goal Phage Evaluation via Randomized-Controlled Clinical Trials Program Product Discovery Preclinical IND-Cleared Phase 2 Partner Pseudomonas CF aeruginosa Respiratory AP-PA02 Infections NCFB Unpartnered Bacteremia U.S. DoD* Staphylococcus au
Slide 7: Delivered on Value-Inflection Milestones
DIVERSIFIED PIPELINE Delivered on Value-Inflection Milestones Positions Both Programs For Pivotal Studies AP-PA02 Positions AP-PA02 for Pivotal Study • Chronic, Pseudomonas aeruginosa CF Ph1b/2a NCFB Ph2 first NCFB Ph2 NCFB Ph2 respiratory infections topline data patient dosed enrollment topline dat
Slide 8: Pipeline Addresses Significant Unmet Need & Market Opportunity Across Multiple Indications
DIVERSIFIED PIPELINE Pipeline Addresses Significant Unmet Need & Market Opportunity Across Multiple Indications Chronic treatment Acute treatment PA PA SA SA Non‐Cystic Fibrosis Prosthetic Joint Complicated Cystic Fibrosis Bronchiectasis Infection Bacteremia U.S. prevalence (treatable patients) >95,
Slide 9: Armata has State-of-the-Art Capabilities in Developing and Manufacturing Phage Therapeutics
WORLD-CLASS CAPABILITIES Armata has State-of-the-Art Capabilities in Developing and Manufacturing Phage Therapeutics From Bench to Clinic Discovery 01 • Phage libraries • Pathogen libraries • Synthetic biologists with phage engineering expertise Preclinical Development • Computational biology team •
Slide 10: Recent Achievements Demonstrate Operational Excellence
WORLD-CLASS CAPABILITIES Recent Achievements Demonstrate Operational Excellence Focus on Pivotal Trial Preparation, Commercialization Aspects Perfected engineered host Optimized excipients for Significantly improved clinical (removal of toxins and extended shelf life of >18 trial efficiencies increa
Slide 11: Manufacturing Infrastructure Creates Competitive Advantage and Alternate Revenue Streams
WORLD-CLASS CAPABILITIES Manufacturing Infrastructure Creates Competitive Advantage and Alternate Revenue Streams State-of-the-art cGMP manufacturing facility • 10,000 square foot purpose-built facility in Los Angeles, California • Essential infrastructure for phage production - Two independent prod
Slide 12: Armata has cGMP Capacity to Support Ph3 Trials and Commercialization
WORLD-CLASS CAPABILITIES Armata has cGMP Capacity to Support Ph3 Trials and Commercialization 10,000 Square Foot Purpose-Built Clean Room Space at U.S. Headquarters High-Throughput Semi-Automated Aseptic Two independent production lines with dedicated upstream and downstream cleanrooms Filling Line,
Slide 13: In-House Quality Control Laboratories
WORLD-CLASS CAPABILITIES In-House Quality Control Laboratories In Readiness For End-of-Phase 2 Meetings, Phase 3 Operations Analytical testing Environmental monitoring, sample receipt from cGMP manufacturing cGLP QC Lab 1 cGLP QC Lab 2 13
Slide 14: Staphylococcus aureus Program (AP-SA02)
Staphylococcus aureus Program (AP-SA02) Complicated Bacteremia Prosthetic Joint Infection
Slide 15: S. aureus Bacteremia Phase 1b/2a Trial Topline Data
S. aureus Bacteremia Phase 1b/2a Trial Topline Data* * Data are preliminary and remains subject to further review and quality control; findings are subject to change pending complete data that will be presented in the future
Slide 16: AP-SA02 in Combination with Antibiotic has the Potential to Become Early Line Standard of Care
AP-SA02 in Combination with Antibiotic has the Potential to Become Early Line Standard of Care in Complicated Staphylococcus aureus Bacteremia • Complicated Staphylococcus aureus bacteremia (SAB) is a serious bloodstream infection with ~54,000 annual U.S.-based hospital episodes • Prognosis with com
Slide 17: Bacteremia Phase 1b/2a diSArm Study Design
Bacteremia Phase 1b/2a “diSArm” Study Design Primary Study Endpoints in Intent-to-Treat (ITT) Population ITT: All subjects that received BAT and at least one dose of AP-SA02 or Placebo (BAT only) Phase 1b: Safety and tolerability of multiple intravenous (IV) doses of AP-SA02 Phase 2a: Clinical outco
Slide 18: AP-SA02 Administered IV Every 6 Hours for 5 Days is Well Tolerated
AP-SA02 Administered IV Every 6 Hours for 5 Days is Well Tolerated Safety Population (N=50) Phase 1b Uncomplicated SAB Phase 2a Complicated SAB AP-SA02 (N=6) Placebo (N=2) AP-SA02 (N=29) Placebo (N=13) n (%) n (%) n (%) n (%) Any adverse events (AEs) 6 (100.0) 2 (100.0) 19 (65.5) 12 (92.3) Any treat
Slide 19: No Serious AEs Related to AP-SA02
No Serious AEs Related to AP-SA02 Only 2 Subjects With AEs Possibly Related to AP-SA02 Phase 1b Uncomplicated SAB Phase 2a Complicated SAB System Organ Class AP-SA02 (N=6) Placebo (N=2) AP-SA02 (N=29) Placebo (N=13) Preferred Term* n (%) n (%) n (%) n (%) Any study drug related treatment-emergent ad
Slide 20: AP-SA02 Improved Clinical Outcome in ITT Population at TOC for AP-SA02 (Day 12)
AP-SA02 Improved Clinical Outcome in ITT Population at TOC for AP-SA02 (Day 12) Significantly Improved Responder Rate (88%) Assessed by Blinded PI Assessed by Blinded PI Assessed by Blinded CEAC Clinical Outcome At TOC for AP-SA02 *p = 0.047 (Day 12)^ 100 100 • Improved responder rate in AP-SA02 90
Slide 21: AP-SA02 Improved Clinical Outcome in ITT Population At All Timepoints
AP-SA02 Improved Clinical Outcome in ITT Population At All Timepoints 100% Clinical Response in AP-SA02 Treated Subjects at TOC BAT and at EOS Assessed by Blinded PI Assessed by Blinded CEAC TOC for BAT EOS TOC for BAT EOS Clinical Outcome at TOC BAT and at EOS (d 18-60) (d 39-81) (d 18-60) (d 39-81
Slide 22: AP-SA02 Effective Against Both MRSA and MSSA
All Subjects With MRSA That Received AP-SA02 Cleared Infection, No Evidence of Relapse AP-SA02 Effective Against Both MRSA and MSSA MRSA Subjects Clinical Outcome Assessed by Blinded PI 100% 100% MRSA Infected Subjects 100 90 89% 80 • 100% of AP-SA02 treated subjects 70 66% 60% clinically responded
Slide 23: Faster Decline of Key Biomarkers in AP-SA02 Treated Subjects
Faster Decline of Key Biomarkers in AP-SA02 Treated Subjects: Supports Clinical Outcome Mean CRP Levels Reached Normal by Day 12^; Remains Elevated in Subjects On BAT Alone 600 CRP Levels Over Time C-reactive Protein (CRP) • General indicator of Inflammation • Predictor of mortality CRP (mg/L) 400 m
Slide 24: Armata's Phage-Specific Drug Manufacturing Platform Creates Significant Competitive Advantage
WORLD-CLASS CAPABILITIES Armata’s Phage-Specific Drug Manufacturing Platform Creates Significant Competitive Advantage, Clinical Differentiators • 10,000 sq ft of U.S. based in-house cGMP excellence creates competitive advantage for internal pipeline • Achieving high purity levels has been a major h
Slide 25: Pseudomonas aeruginosa Program (AP-PA02)
Pseudomonas aeruginosa Program (AP-PA02) Cystic Fibrosis (CF) Non-CF Bronchiectasis (NCFB)
Slide 26: Ph1b/2a SWARM-P.a. Study With Inhaled AP-PA02: Completed 1Q23
Ph1b/2a SWARM-P.a. Study With Inhaled AP-PA02: Completed 1Q23 Outpatient Study in CF Adults with Chronic Pulmonary Pseudomonas aeruginosa Infections Study Design (25 US sites) Study Objectives Key Inclusion Criteria ≥10⁴ CFU of Pa per gram of induced sputum at Screening Pa isolates sensitive to AP-P
Slide 27: Learnings for SWARM-P.a. Ph1b/2a CF Study
Learnings for SWARM-P.a. Ph1b/2a CF Study AP-PA02 Well-Tolerated with Consistent Exposures by Dose Learnings Safety and Tolerability for up to 10 days bid dosing • No dose-limiting toxicity • No AEs >Grade 1 attributed to study drug: Grade 1 AEs appear to be intermittent with quick recovery Distribu
Slide 28: NCFB Phase 2 Trial Topline Data
NCFB Phase 2 Trial Topline Data* * Data are preliminary and remains subject to further review and quality control; findings are subject to change pending complete data that will be presented in the future
Slide 29: NCFB Phase 2 Tailwind Study: Completed 3Q24
NCFB Phase 2 Tailwind Study: Completed 3Q24 Evaluated AP-PA02 as Monotherapy and in Combination with Inhaled Antibiotics AP-PA02 nebulized q12h x 10 days Subjects dosed at home Started with highest dose from CF study (increased dose 2X after lead in) Evaluated AP-PA02 exposures in correlatio
Slide 30: Efficacy Analysis Per SAP Resulting in Significant Decrease in Power
Efficacy Analysis Per SAP (10/48 Subjects Excluded From Analysis) Resulting in Significant Decrease in Power to See Changes; Therefore, Also Ran ITT Analysis Endpoint: Change in CFU at Day 17 Compared to Baseline Subjects Treated with Highest Dose vs. Placebo* Highest Dose = 3E11 PFU Cohort A Cohort
Slide 31: POST HOC P. aeruginosa Efficacy Data
POST HOC P. aeruginosa Efficacy Data ITT Population Analysis - All 48 Subjects Pa density Change in Pa density from Baseline: Treated vs. Placebo* (baseline vs. each day within each group)** d24: P=0.015 Treated Placebo d17: P=0.05 (p-value) (p-value) 4 Baseline vs Day 5 0.8 0.38 3 Day 10 0.03 0.76
Slide 32: POST HOC ITT Independent Cohort Analysis
POST HOC ITT Independent Cohort Analysis – Includes All Subjects That Received Any Phage or Placebo AP-PA02 Alone is as Effective as AP-PA02 Plus Antibiotics AP-PA02 Treated (Cohort A or B; All Treated vs. All Placebo)* P=0.06 P=0.66 P=0.09 P=0.44 P=0.07 P=0.16 P=0.02* P=0.09 4 P=0.16 P=0.97 3 2 ΔCF
Slide 33: Corporate Summary
Corporate Summary
Slide 34: Leadership and Board of Directors
LEADERSHIP AND PARTNERS Leadership and Board of Directors Diverse Public Company Drug Development Expertise Management Board of Directors Deborah Birx, MD Peter Hubbard, MBA CEO VP, Operations Jules Haimovitz Robin Kramer, Chair Todd Peterson, PhD Pierre Kyme, PhD Bhaumik Patel CBO Quality Assurance
Slide 35: Strong Relationships with Partners with Demonstrated Interest in Supporting Development of Phage Therapy
LEADERSHIP AND PARTNERS Strong Relationships with Partners with Demonstrated Interest in Supporting Development of Phage Therapy Underscores Credibility of Armata’s Clinical Programs Armata Partnerships Future Funding Options $5M Therapeutics Development Award • Foundation Support: CFF • Support Ph1
Slide 36: Funding and Capitalization
Funding and Capitalization Cash Position • $11.7 million in unrestricted cash and cash equivalents at March 31, 2025* Financing History • Q1 2020: $25M private placement of common stock and warrants with Innoviva, Inc. • Q1 2021: $20M private placement of common stock and warrants with Innoviva Stra
Slide 37: Strong Global IP Position Through Pending and Issued Patents
Strong Global IP Position Through Pending and Issued Patents 14 Patent Families, Long-Life Patents, Patents Granted in all Major Jurisdictions Armata’s patents and applications cover: • Therapeutic phage cocktails (Staphylococcus and Pseudomonas) and uses thereof • Synthetic phage and methods of man
Slide 38: Grateful to the patients, clinical research team and site investigators
Grateful to the patients, clinical research team and site investigators that make this work possible, and to our funders We are privileged to work across We are grateful to the patient We are effective due to top-notch the United States and Australia volunteers that understand the employees that wor
Slide 39: www.armtapharma.com
PURPOSEFUL @ PRECISE POWERFUL www.armtapharma.com
Armata Pharmaceuticals — Investor Presentation (May 2025) on 6ix